118 Results
Sort By:
Published on February 7, 2024
Colorectal and pancreatic cancers—the second and third leading causes of cancer death, respectively—often have mutations in the KRAS protein. Now, a new vaccine that targets KRAS has shown encouraging early results as a potential off-the-shelf treatment for patients with pancreatic cancer or colorectal cancer, according to a study co-led by…
Published on January 9, 2024
An experimental cancer vaccine developed by Elicio Therapeutics to target tumors with KRAS mutations has achieved good results in a Phase I trial in patients with residual pancreatic and colorectal cancer following earlier treatment. As reported in Nature Medicine, the majority of patients in the study (84%) had a T…
Published on October 10, 2023
Bristol Myers Squibb (BMS) has signed a $4.8 billion deal to buy Mirati Therapeutics and its cancer drug KRAZATI, which targets KRAS. In December 2022, KRAZATI (adagrasib) was granted accelerated U.S. Food and Drug Administration (FDA) approval for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic Non-Small…
Published on August 23, 2023
KRAS is one of the most common cancer-causing genes in humans. To date, researchers have been unable to design a small molecule to block its active form because it lacks a binding pocket. Now, researchers report in Science how they have created a molecular glue that allows the binding of…
Published on March 20, 2023
A collaborative study by Spanish researchers at the Cancer Research Center (CSIC-University of Salamanca) and The Experimental Oncology group at CNIO (Centro Nacional de Investigaciones Oncológicas) has found the mechanism of KRAS inhibitor tumor resistance and suggest that it can be overcome by more potent drugs or degraders. The study…
Published on December 22, 2022
KRAS inhibitors made substantial progress this week as both Mirata (adagrasib for colorectal cancer) and Amgen (sotorasib for pancreatic cancer) shared positive trial results in the New England Journal of Medicine. Mirata also netted an FDA Breakthrough Therapy Designation (BTD) for adagrasib (KRAZATI) in combination with cetuximab in patients with KRASG12C-mutated,…
Published on December 14, 2022
Researchers from the University of Pennsylvania have discovered that a small molecule KRAS-targeted therapy stopped cancer growth or shrank tumors in animal models of pancreatic cancer. They found that the drug inhibits the activity of the most common KRAS mutation in pancreatic cancer and simultaneously boosts T cells mediated immunity.…
Published on December 7, 2022
Researchers at the University of Pennsylvania School of Medicine, have shown that a small molecule inhibitor of the cancer-causing gene mutation KRAS successfully shrinks tumors and stops cancer growth in preclinical models for pancreatic cancer. Found in nearly 30 percent of all human tumors, KRAS is one of the most…
Published on October 21, 2022
HOOKIPA Pharma has announced a strategic collaboration and license agreement with Roche to develop its HB-700 immunotherapy for KRAS-mutated cancers and a second undisclosed drug. This is HOOKIPA’s first oncology licensing collaboration. The company is developing a new class of immunotherapies based on its proprietary replicating arenavirus platform. HOOKIPA will…
Published on September 13, 2022
The KRAS-inhibitor race came into attention this week when non-small cell lung cancer patients with a KRAS G12C mutation had higher progression-free survival (PFS) and objective response rate (ORR) with Amgen’s KRAS inhibitor Lumakras (sotorasib) compared with docetaxel, according to results from a Phase III trial. The data were presented yesterday…
Published on July 20, 2022
Scientists have discovered that the KRAS gene mutation, which occurs early in the transformation to cancer, leads to the abundant release of a particular type of non-coding RNA that may be useful in early cancer diagnosis. The research team from UC Santa Cruz examined the effects of mutations in the…
Published on March 10, 2022
Researchers have successfully used an FDA-approved drug to stop the growth of tumors driven by mutations in the RAS gene, which are famously difficult to treat and account for about one in four cancer deaths. The achievement takes advantage of the discovery that cells carrying KRAS gene mutations —which are…
Published on November 12, 2021
Highlighting the need to monitor patients who have undergone CRISPR-Cas9-based gene therapy for cancer-related mutations, researchers at Sanford Burnham Prebys have shown that gene editing, specifically gene knockout (KO) using CRISPR-Cas9 technology, can favor cells with mutated forms of p53 or KRAS genes linked to cancer. “Our study shows that…
Published on October 7, 2021
Two possible add-on drugs that could help fight resistance to KRAS inhibitors such as Amgen’s sotorasib (Lumakras) have been discovered, according to research presented at the 2021 Molecular Targets and Cancer Therapeutics conference. The studies are both early stage—one Phase Ib testing afatinib and one testing an Aurora Kinase A…
Published on June 7, 2021
The first ever drug to target KRAS mutated cancers—Amgen’s Lumakras (sotorasib)—has been given accelerated approval by the FDA based on results from a Phase II trial. Two companion diagnostic tests developed by Qiagen and Guardant—the QIAGEN therascreen KRAS RGQ PCR (tissue) and the Guardant360 CDx (plasma) kits—have also been approved…